Medicineworld.org: Diabetes Drug With Chemotherapy
Subscribe To Cancer Blog RSS Feed
Diabetes Drug With Chemotherapy
Combining a platinum chemotherapy agent and the diabetes drug rosiglitazone halted or shrank mouse tumors as much as three times more effectively than either of the drugs given alone, as per the article in the recent issue of Cancer Cell.
If pairing the drugs has the same synergistic effect in humans, the scientists say, it could improve control of ovarian, lung and other cancers routinely treated with platinum-based chemotherapy, to which tumors eventually become resistant. Moreover, the experiments suggest the combination might extend the use of platinum drugs to other cancers where they haven't previously been shown to be effective.
"There's still a huge gulf between these experiments and human cancers," said Bruce Spiegelman, PhD, senior author of the report. "But it's worked in every animal model of cancer weve looked at, and I think theres a fair chance it will help people".
Dana-Farber scientists are already drawing up plans for initial clinical trials, which could begin sometime this year.
"We really see a way forward here to improve the chemotherapy's effectiveness for multiple forms of cancer," said George Demetri, MD, a Dana-Farber researcher who is preparing a proposal for a pilot study of rosizitaglone and platinum chemotherapy drugs in lung and ovary cancer and sarcomas.
If a pilot study shows promising activity, the combination would need to be compared with standard chemotherapy in larger phase 2 and phase 3 trials involving a number of hundreds of patients.
Rosizitaglone, sold under the name Avandia, enhances insulin receptors' sensitivity in diabetics whose pancreas secretes too little insulin. It was approved in 1999 for use by patients with type 2 diabetes to help control blood sugar levels. An estimated 5 million people in the U.S. take Avandia or a similar drug, piozitaglone, which is sold as Actos.
Both drugs work by activating PPAR-gamma, a transcription factor that functions as a master regulator of fat development in the body, a function discovered in the Spiegelman lab in 1994. Spiegelman and others found that certain PPAR-gamma-activating compounds, called PPAR-gamma ligands, caused cancer cells to stop growing and become more mature, or differentiated. Therefore, Spiegelman and others felt it was a logical step to try PPAR-gamma ligands as cancer therapy, but several small clinical trials found rosiglitazone alone was ineffective against several cancer types.
Despite this setback, and because rosizitaglone was well-tolerated by patients in comparison to standard cancer drugs, Dana-Farber scientists believed it was worthwhile to try it and similar PPAR-gamma ligands in a different context, said Geoffrey Girnun, PhD, a researcher in Spiegelman's laboratory and lead author of the Cancer Cell report. "After discussing it with other Dana-Farber researchers, we decided to try these agents in combination with platinum-based drugs, and in several different cell lines, we saw positive results," said Girnun.
In addition to rosizitaglone, the researchers tested pioglitazone and an experimental compound made by Glaxo Smith Kline, combining each of them with cisplatin, carboplatin and oxalyplatin -- all usually used chemotherapy drugs that destroy cancer cells by damaging their DNA.
When non small-cell lung cancer cell lines were treated with rosizitaglone alone, there was no effect on growth. Carboplatin alone reduced growth of the cancer cells by about 60 percent. But when both drugs were administered, cell growth was reduced by 80 percent. The drugs were also tested individually and together on ovary cancer cell lines that normally are resistant to chemotherapy -- and proved capable of reducing growth of the cancer cells by 90 percent. Even when applied to colon cancer cells, a type of cancer not commonly treated with platinum drugs, rosiglitazone and carboplatin lowered the growth rate by 70 percent. (Rosizitaglone did not show the same positive effect when paired with oxalyplatin.).
The drug combination also had striking growth-suppressing results when given to mice with human lung and ovarian tumors implanted under their skin and in mice that had received a chemical that causes them to develop colon cancer, explained Spiegelman, who is also a professor of cell biology at Harvard Medical School.
The experiments showed that the PPAR-gamma ligands suppressed the activity of metallothioneine genes, which are believed to trigger the development of cancer cells resistance to platinum chemotherapy.
"Our finding that PPAR-gamma activation dramatically increases the efficacy of carboplatin, potentially causing tumor stasis or even tumor shrinkage could represent a significant advance in chemotherapy," the scientists wrote.
Posted by: Janet Source
Did you know?
A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, researchers from Dana-Farber Cancer Institute report. Combining a platinum chemotherapy agent and the diabetes drug rosiglitazone halted or shrank mouse tumors as much as three times more effectively than either of the drugs given alone, as per the article in the recent issue of Cancer Cell.
Medicineworld.org: Diabetes Drug With Chemotherapy
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.